In 2002, Theralight, Inc. received US FDA 510(k) clearance to market its desktop UV120-2 UVA/UVB phototherapy system for treating psoriasis, vitiligo, eczema, and seborrhoeic dermatitis
TheraLight, LLC has announced acquisition of medical assets (Credit: Gerd Altmann from Pixabay)
TheraLight, LLC, an FDA-registered manufacturer and distributor of cutting-edge light therapy products, recently announces it has acquired the assets from Theralight, Inc., a manufacturer of phototherapy devices.
The assets acquisition includes a portfolio of products, trademarks, and FDA 510k clearances. Theralight, Inc. was privately owned and founded in July 2000 with operations from facilities located in Carlsbad, California. The company created the first hands-free, light therapy system and had the single worldwide license from Osram Sylvania to Icetron lamp technology for the treatment of skin disorders.
“We are pleased to acquire the assets from the owners of Theralight, Inc.,” stated Charles Vorwaller, president & CEO. “This acquisition provides us an opportunity to expand our company in a number of new ways, including the addition of the DuaLight and VersaClear products. There are many advantages to these non-laser products over competitors that sell Excimer lasers. The good news is that these treatments are covered by insurance companies.”
In 2002, Theralight, Inc. received US FDA 510(k) clearance to market its desktop UV120-2 UVA/UVB phototherapy system for treating psoriasis, vitiligo, eczema, and seborrhoeic dermatitis. Weighing less than 20lbs, the product was the first targeted phototherapy system to emit either UVA or UVB bands of ultra-violet light, providing physicians with the flexibility of treating patients using either PUVA (UVA with psoralen), or UVB.
“As a company, we remain committed to delivering innovation and world class technology designed to provide positive outcomes for both medical professional and their patients,” noted According to Justin Vorwaller, MBA, COO of TheraLight, LLC,
This acquisition transaction was advised and handled through Thorpe North & Western’s David W. Osborne, a registered patent attorney; TheraLight, LLC plans to integrate the acquired assets in quarter two of 2020.
Source: Company Press Release